2
|
Pelosi C, Thiel P, Bart S, Amossé J, Jean-Jacques J, Thoisy JC, Crouzet O. The contributions of enchytraeids and earthworms to the soil mineralization process in soils with fungicide. Ecotoxicology 2021; 30:1910-1921. [PMID: 34379246 DOI: 10.1007/s10646-021-02452-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 07/02/2021] [Indexed: 06/13/2023]
Abstract
Pesticides may harm soil organisms such as earthworms and enchytraeids, but knowledge is lacking on their relative sensitivity to these chemicals and the consequences on soil functions. The aim of this study was to assess the impact of exposure to a commercial fungicide formulation (Swing® Gold, containing dimoxystrobin and epoxiconazole) on the function of earthworms (Aporrectodea caliginosa) and enchytraeids (Enchytraeus buchholzi) in soil organic matter (SOM) mineralization. The soil organisms were incubated alone and together in a 26-day laboratory experiment. At the recommended field rate, the fungicide induced a decrease in the SOM mineralization and a delay in the maximum daily CO2 emissions compared to the control soil without fungicide. Soil fauna also influenced SOM mineralization with a higher cumulated CO2 release after 26 days in the control soil with earthworms (by 21%) than without fauna. When both earthworms and enchytraeids were present, SOM mineralization did not increase, and there was a negative effect on earthworm weight gain. Finally, an alteration of fauna influence with treatment was observed from day 19, meaning that the effect of fauna on SOM mineralization changed with fungicide treatment. Earthworms no longer promoted SOM mineralization when fungicide was present at three-fold the recommended field rate. The effects of enchytraeids on SOM mineralization were similar with and without fungicide exposure. This study underlines the importance of considering the relative sensitivity of soil organisms to environmental factors and interactions between them when assessing soil functioning.
Collapse
Affiliation(s)
- C Pelosi
- INRAE, Avignon Université, UMR EMMAH, F-84000, Avignon, France.
| | - P Thiel
- INRAE, AgroParisTech, Université Paris-Saclay, UMR ECOSYS, F-78026, Versailles, France
| | - S Bart
- INRAE, AgroParisTech, Université Paris-Saclay, UMR ECOSYS, F-78026, Versailles, France
- Department of Environment and Geography, University of York, YO10 5NG, York, UK
| | - J Amossé
- INRAE, AgroParisTech, Université Paris-Saclay, UMR ECOSYS, F-78026, Versailles, France
| | - J Jean-Jacques
- INRAE, AgroParisTech, Université Paris-Saclay, UMR ECOSYS, F-78850, Thiverval-Grignon, France
| | - J-C Thoisy
- INRAE, AgroParisTech, Université Paris-Saclay, UMR ECOSYS, F-78026, Versailles, France
| | - O Crouzet
- INRAE, AgroParisTech, Université Paris-Saclay, UMR ECOSYS, F-78026, Versailles, France
| |
Collapse
|
4
|
Bernasconi-Elias P, Hu T, Jenkins D, Firestone B, Gans S, Kurth E, Capodieci P, Deplazes-Lauber J, Petropoulos K, Thiel P, Ponsel D, Hee Choi S, LeMotte P, London A, Goetcshkes M, Nolin E, Jones MD, Slocum K, Kluk MJ, Weinstock DM, Christodoulou A, Weinberg O, Jaehrling J, Ettenberg SA, Buckler A, Blacklow SC, Aster JC, Fryer CJ. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 2016; 35:6077-6086. [PMID: 27157619 PMCID: PMC5102827 DOI: 10.1038/onc.2016.133] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Accepted: 03/07/2016] [Indexed: 01/07/2023]
Abstract
Notch receptors have been implicated as oncogenic drivers in several cancers, the most notable example being NOTCH1 in T-cell acute lymphoblastic leukemia (T-ALL). To characterize the role of activated NOTCH3 in cancer, we generated an antibody that detects the neo-epitope created upon gamma-secretase cleavage of NOTCH3 to release its intracellular domain (ICD3), and sequenced the negative regulatory region (NRR) and PEST domain coding regions of NOTCH3 in a panel of cell lines. We also characterize NOTCH3 tumor-associated mutations that result in activation of signaling and report new inhibitory antibodies. We determined the structural basis for receptor inhibition by obtaining the first co-crystal structure of a NOTCH3 antibody with the NRR protein and defined two distinct epitopes for NRR antibodies. The antibodies exhibit potent anti-leukemic activity in cell lines and tumor xenografts harboring NOTCH3 activating mutations. Screening of primary T-ALL samples reveals that two of 40 tumors examined show active NOTCH3 signaling. We also identified evidence of NOTCH3 activation in 12 of 24 patient-derived orthotopic xenograft models, two of which exhibit activation of NOTCH3 without activation of NOTCH1. Our studies provide additional insights into NOTCH3 activation and offer a path forward for identification of cancers that are likely to respond to therapy with NOTCH3 selective inhibitory antibodies.
Collapse
Affiliation(s)
- P Bernasconi-Elias
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - T Hu
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - D Jenkins
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - B Firestone
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - S Gans
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - E Kurth
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - P Capodieci
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - J Deplazes-Lauber
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - K Petropoulos
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - P Thiel
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - D Ponsel
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - S Hee Choi
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - P LeMotte
- Department of Biologics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - A London
- Department of Biologics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - M Goetcshkes
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - E Nolin
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - M D Jones
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - K Slocum
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - M J Kluk
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - D M Weinstock
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA
| | - A Christodoulou
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA
| | - O Weinberg
- Pathology Children Hospital Boston, Boston, MA, USA
| | - J Jaehrling
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - S A Ettenberg
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - A Buckler
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - S C Blacklow
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.,Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - J C Aster
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.,Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - C J Fryer
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| |
Collapse
|
5
|
Herrmann WJ, Thiel P, Weinert K. [Contract Conditions for GPs in Training while Working in Ambulatory Care]. Gesundheitswesen 2014; 78:402-6. [PMID: 25372653 DOI: 10.1055/s-0034-1390449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND In Germany, the situation of GPs in training has received growing attention. Central funding of GPs in training who are working in ambulatory care has been increased up to 3 500 Euros/month. However, the contract conditions of GPs in training who are working in ambulatory care have been unknown as yet. METHODS An online survey was undertaken. We recruited GPs in training by snowball sampling making use of national and local organisations of GPs and GPs in training. Our questionnaire consisted of questions concerning sociodemographic variables, gross wage, working hours, holidays and free days for educational purposes. Data were analysed by descriptive statistical methods. RESULTS 152 participants fulfilled the inclusion criteria. 127 were full time GPs in training. The median of gross wage was 3 500 Euros/month, the mean gross wage was 3 878 Euros/month. The gross wage per hour was lower than that for GPs in training who are working in hospitals. Especially part time GPs in training had a lower gross wage per hour. One third of the GPs in training had no free days for educational purposes. More than half of the GPs in training had a weekly meeting with their supervisor, however, more than one third of GPs in training had no or only irregular meetings with their supervisor. CONCLUSIONS In Germany, GPs in training earn in ambulatory care less than in hospital care. They do not have sufficient free days for educational purposes and often there is a lack of supervision. This seems to indicate that GPs in training are mainly considered as cheap coworkers instead of trainees.
Collapse
Affiliation(s)
- W J Herrmann
- Institut für Allgemeinmedizin, Otto-von-Guericke-Universität Magdeburg, Magdeburg
| | - P Thiel
- Junge Allgemeinmedizin Deutschland, Frankfurt
| | - K Weinert
- Junge Allgemeinmedizin Deutschland, Frankfurt
| |
Collapse
|